Anafranil
4 customer reviewsAnafranil is a tricyclic antidepressant containing clomipramine hydrochloride. It is used for OCD, depression, and panic disorder. It helps by blocking serotonin reuptake and reducing obsessive thoughts and anxiety-driven behaviours.
What is it?
Anafranil, containing the active ingredient clomipramine hydrochloride, is a tricyclic antidepressant primarily used to treat obsessive-compulsive disorder (OCD), depression, and panic disorder. It is used in adults and, in selected cases, adolescents under specialist care where intrusive thoughts, compulsions, or anxiety symptoms are impairing daily function. Clomipramine works mainly by blocking serotonin reuptake (and also affects norepinephrine), which can reduce obsessive thoughts and ease anxiety-driven behaviours.
What Anafranil is and what conditions it treats
Anafranil is a tricyclic antidepressant (TCA) in the wider group of antidepressants. Its generic name is clomipramine (also written as clomipramine hydrochloride), and it has a long-standing role in OCD management, where it can be more effective than many other antidepressants for obsessive symptoms in day-to-day practice. It is not a “quick fix”, and the benefit tends to build with steady dosing over weeks rather than hours.
Common reasons clinicians prescribe clomipramine include:
- Obsessive compulsive disorder (OCD): intrusive thoughts and repetitive behaviours driven by anxiety.
- Depression: low mood with reduced motivation, sleep/appetite change, and impaired function.
- Panic disorder: recurrent panic attacks and anticipatory anxiety.
- Phobias: persistent, impairing fear responses to specific situations.
- Trichotillomania: compulsive hair pulling, often with tension relief after pulling.
- Cataplexy and narcolepsy: sometimes used to reduce cataplexy episodes linked with narcolepsy (specialist-directed).
- Enuresis: selected cases of night-time bedwetting, typically when other approaches fail (specialist-directed).
- Premature ejaculation: off-label use in selected patients when clinically appropriate.
Composition
Anafranil, containing the active ingredient clomipramine hydrochloride, is a tricyclic antidepressant primarily used to treat obsessive-compulsive disorder (OCD), depression, and panic disorder. It is used in adults and, in selected cases, adolescents under specialist care where intrusive thoughts, compulsions, or anxiety symptoms are impairing daily function. Clomipramine works mainly by blocking serotonin reuptake (and also affects norepinephrine), which can reduce obsessive thoughts and ease anxiety-driven behaviours.
What Anafranil is and what conditions it treats
Anafranil is a tricyclic antidepressant (TCA) in the wider group of antidepressants. Its generic name is clomipramine (also written as clomipramine hydrochloride), and it has a long-standing role in OCD management, where it can be more effective than many other antidepressants for obsessive symptoms in day-to-day practice. It is not a “quick fix”, and the benefit tends to build with steady dosing over weeks rather than hours.
Common reasons clinicians prescribe clomipramine include:
- Obsessive compulsive disorder (OCD): intrusive thoughts and repetitive behaviours driven by anxiety.
- Depression: low mood with reduced motivation, sleep/appetite change, and impaired function.
- Panic disorder: recurrent panic attacks and anticipatory anxiety.
- Phobias: persistent, impairing fear responses to specific situations.
- Trichotillomania: compulsive hair pulling, often with tension relief after pulling.
- Cataplexy and narcolepsy: sometimes used to reduce cataplexy episodes linked with narcolepsy (specialist-directed).
- Enuresis: selected cases of night-time bedwetting, typically when other approaches fail (specialist-directed).
- Premature ejaculation: off-label use in selected patients when clinically appropriate.
How to use?
How to take Anafranil: dosage and administration
Anafranil dosing is individualized. For OCD and panic disorder, prescribers often begin low and increase gradually to reduce early side effects like drowsiness, constipation, and dizziness.
Typical prescribing patterns (doctor-directed):
- Adult dose: often starts low, then increases stepwise over days to weeks; many OCD patients need moderate-to-higher daily doses for full effect.
- Child dose: used only when a specialist decides the benefit outweighs risk; dosing is weight- and tolerability-based, with close monitoring.
- Renal dose: kidney disease can change exposure and tolerability; prescribers may use slower titration and lower targets in significant impairment.
- Administration: swallow tablets with water; taking it with food can reduce nausea and stomach upset.
Starting and adjusting dosage
Dose titration matters with TCAs. Going up too fast is a common reason people stop early, even when the medication could have worked well for OCD. For many patients, meaningful OCD symptom reduction appears after 2–6 weeks at a stable therapeutic dose, and sometimes longer for full benefit.
Taking Anafranil with food
Taking Anafranil with food can smooth out early nausea and reduce “stomach flipping” sensations. If morning dosing causes daytime sleepiness, clinicians often move dosing later in the day rather than lowering a dose that is starting to help.
How does it work?
- Route: Oral tablets only.
- Dose: Start with 25 mg once daily; increase gradually as directed up to 100–250 mg/day for obsessive-compulsive symptoms, depending on response and tolerability.
- Frequency: Take 1–3 times/day if the total daily dose is split.
- Timing: Take with food or after meals to reduce stomach upset; if drowsiness occurs, the larger portion may be taken at bedtime.
- Duration: Use daily for several weeks to months; do not stop abruptly without medical advice.
- Administration: Swallow the pills with water and take them at the same times each day.
Indications
Anafranil is prescribed for obsessive-compulsive disorder, depression, panic disorder, phobias, trichotillomania, selected cases of cataplexy and narcolepsy, selected cases of enuresis, and off-label use for premature ejaculation.
Comparison
Anafranil is a TCA, and that shapes both its advantages and its drawbacks. For OCD, clomipramine is often viewed as one of the most potent serotonin reuptake inhibitors in real-world practice; the trade-off is a heavier side-effect burden than many SSRIs. Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are often tried first because they are easier to tolerate and safer in overdose. Agents like vortioxetine are used for depression and cognition symptoms, yet they are not the classic first-line choice for OCD compared with SSRIs or clomipramine.
| Option | Class | Typical place in care |
|---|---|---|
| Anafranil (clomipramine) | Tricyclic antidepressant (TCA) | OCD with strong obsessive symptoms; depression/panic in selected patients |
| Fluoxetine | SSRI | Often first-line for depression and OCD due to tolerability |
| Vortioxetine | Serotonergic antidepressant | Depression where cognitive symptoms are prominent |
One-sentence trade-off: Anafranil can work when SSRIs fall short, yet constipation, sedation, and sexual side effects stop some people from staying on it.
Contraindications
- Concomitant use with MAOIs such as phenelzine or isocarboxazid
- Significant seizure risk or conditions that lower seizure threshold
- Bipolar disorder or schizophrenia when antidepressant-induced activation is a concern
- Older adults when anticholinergic burden is likely to be dose-limiting
- Narrow-angle glaucoma risk
- Urinary retention or prostate enlargement risk
- History of cardiac rhythm problems where TCA-related rhythm effects are a concern
- Hypersensitivity to clomipramine or related tricyclic antidepressants
Not recommended for
Anafranil is not a good fit if you have bipolar disorder, schizophrenia, a seizure tendency, heart rhythm concerns, narrow-angle glaucoma, or trouble passing urine. It also needs extra caution in older adults because constipation, confusion, and falls can become more likely. If you are taking an MAOI or other medicines that raise serotonin, this is especially important to discuss before starting.
Side effects
Side effects with Anafranil are real, and they are also predictable. Clomipramine has anticholinergic effects (dry mouth, constipation, blurred vision), can cause sedation, and may affect heart rhythm in susceptible patients.
Commonly reported adverse effects include:
- Drowsiness, fatigue, slowed reaction time
- Dizziness, sweating, tremor
- Dry mouth, constipation, nausea
- Blurred vision or light sensitivity
- Urinary hesitation (difficulty starting urination)
- Sexual side effects (reduced libido, delayed orgasm)
- Weight change in some patients
Serious effects that need urgent medical attention:
- Fainting, palpitations, chest pain, or new shortness of breath (possible rhythm disturbance)
- Confusion, severe agitation, fever with muscle rigidity (possible serotonin toxicity risk, usually with interacting drugs)
- Suicidal thoughts, sudden mood elevation, or reduced need for sleep (possible bipolar activation)
A small but important nuance: TCAs can worsen narrow-angle (closed-angle) glaucoma and can trigger urinary retention in men with prostate enlargement, even at doses that are helpful for OCD.
Common mistakes
Small errors can change tolerability a lot with TCAs.
Mistakes that commonly lead to poor outcomes:
- Stopping suddenly after feeling sleepy or constipated for a few days, then getting rebound insomnia, irritability, and “electric shock” sensations.
- Taking the whole day’s dose in the morning, then struggling with daytime sedation and giving up.
- Treating constipation as minor, then ending up with severe discomfort and stopping the medication.
- Mixing with alcohol “to sleep”, then waking up groggy and dizzy with poor coordination.
- Not mentioning past mania, hypomania, or family bipolar history, then being surprised by agitation or reduced need for sleep during titration.
Doctor opinions
Doctors usually reach for Anafranil when the problem is dominated by obsessions and compulsions that do not respond well enough to first-line options, or when a patient previously had a clear response to clomipramine. Psychiatrists also tend to respect the side-effect profile and build the dose more slowly than with SSRIs, because constipation, sedation, and orthostatic dizziness are the reasons people quit early.
Frequently asked questions
Clinical guidance for OCD pharmacotherapy expects a gradual build of benefit, often over several weeks, and many patients need a stable therapeutic dose before the change becomes obvious. A common real-life timeline is early tolerability changes in week 1–2, then reduced ritual time and urge intensity from week 3 onward, with further gains after that. NICE OCD guidance (updated documents are maintained through 2025) supports adequate duration at an effective dose before judging response and often pairs medication with CBT with exposure and response prevention. Dose changes should be paced because side effects can appear faster than symptom relief.
Anafranil is not classed as an addictive drug in the way benzodiazepines or opioids are. Still, stopping abruptly can trigger discontinuation symptoms such as nausea, insomnia, vivid dreams, irritability, and flu-like feelings. WHO medicine safety materials describe discontinuation phenomena across antidepressant classes and recommend gradual tapering when treatment ends. If you have taken it for months, a planned taper is usually far easier than a sudden stop.
Alcohol can amplify sedation, dizziness, and slowed reaction time from clomipramine, and that can be dangerous for driving or operating machinery. People who drink also report poorer sleep quality on TCAs, even if alcohol feels sedating at first. MOHAP-aligned safety counselling in the UAE typically advises avoiding alcohol with sedating psychotropic medicines because impairment is additive and unpredictable across individuals. If alcohol is a regular part of your routine, it is worth planning dosing time carefully with your prescriber.
Anafranil S.R refers to a sustained-release approach, designed to release medication more gradually across the day. Some patients experience smoother tolerability (less peak-related dizziness or nausea), while others prefer immediate-release flexibility for dose timing. The core active ingredient is still clomipramine hydrochloride, and the clinical goal is the same—consistent exposure that reduces OCD and anxiety symptoms. Switching between release patterns is a prescriber decision because timing and side effects can shift.
Sleepiness is common early on and is dose-related. Clinicians often respond by shifting more of the dose to evening, splitting the dose, or slowing titration rather than abandoning treatment immediately, since OCD benefits often come later. EMA medicine information for clomipramine supports titration strategies to improve tolerability while maintaining therapeutic intent. If sleepiness is sudden, severe, or paired with fainting or palpitations, urgent assessment is needed.
Anafranil has historically been associated with Novartis Pharma AG in many markets, and brand ownership can vary by region over time through licensing and distribution arrangements. What matters clinically is that Anafranil refers to clomipramine hydrochloride tablets at the stated strength, produced under regulated pharmaceutical quality systems. EMA documentation for clomipramine focuses on the active ingredient’s safety and efficacy profile, independent of brand owner naming conventions. If brand continuity is important for you due to tolerability, staying consistent with the same product is a reasonable preference to discuss with your prescriber.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Anafranil — Comparison with alternatives
Anafranil Current
Zoloft Best price
Pristiq
Paxil
Sinequan Best rated
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2023). Summary of Product Characteristics (SmPC) — clomipramine ↑
- European Medicines Agency (EMA) (2023). Quality and bioequivalence guidance for generic medicines ↑
- Ministry of Health and Prevention (MOHAP) (2024). Antidepressant medicines: patient counselling and safety advice ↑
- World Health Organization (WHO) (2025). Poisoning prevention and management: tricyclic antidepressants ↑
- National Institute for Health and Care Excellence (NICE) (2025). Obsessive-compulsive disorder and body dysmorphic disorder: treatment ↑